Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

436 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
Pujade-Lauraine E, Guastalla JP, Weber B, Curé H, Orfeuvre H, Mousseau M, Vincent P, Diéras V, Tubiana-Mathieu N, Jacquin JP, Mignot L, Leduc B, Paraïso D, Viens P. Pujade-Lauraine E, et al. Among authors: viens p. Semin Oncol. 1997 Oct;24(5 Suppl 15):S15-30-S15-35. Semin Oncol. 1997. PMID: 9346219 Clinical Trial.
High-dose therapy and autologous bone marrow transplantation in first complete or partial remission for poor prognosis Hodgkin's disease.
Fleury J, Legros M, Colombat P, Cure H, Travade P, Tortochaux J, Dionet C, Chollet P, Linassier C, Lamagnere JP, Blaise D, Viens P, Maraninchi D, Plagne R. Fleury J, et al. Among authors: viens p. Leuk Lymphoma. 1996 Jan;20(3-4):259-66. doi: 10.3109/10428199609051616. Leuk Lymphoma. 1996. PMID: 8624465 Clinical Trial.
Efficacy and safety of the paclitaxel and carboplatin combination in patients with previously treated advanced ovarian carcinoma. A multicenter GINECO (Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens) phase II study.
Guastalla JP, Pujade-Lauraine E, Weber B, Cuŕe H, Orfeuvre H, Mousseau M, Vincent P, Diéras V, Tubiana-Mathieu N, Jacquin JP, Mignot L, Leduc B, Viens P, Pariso D. Guastalla JP, et al. Among authors: viens p. Ann Oncol. 1998 Jan;9(1):37-43. doi: 10.1023/a:1008211909585. Ann Oncol. 1998. PMID: 9541681 Free article. Clinical Trial.
First-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial).
Viens P, Palangié T, Janvier M, Fabbro M, Roché H, Delozier T, Labat JP, Linassier C, Audhuy B, Feuilhade F, Costa B, Delva R, Cure H, Rousseau F, Guillot A, Mousseau M, Ferrero JM, Bardou VJ, Jacquemier J, Pouillart P. Viens P, et al. Br J Cancer. 1999 Oct;81(3):449-56. doi: 10.1038/sj.bjc.6690714. Br J Cancer. 1999. PMID: 10507769 Free PMC article. Clinical Trial.
Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patients.
Alexandre J, Bleuzen P, Bonneterre J, Sutherland W, Misset JL, Guastalla J, Viens P, Faivre S, Chahine A, Spielman M, Bensmaïne A, Marty M, Mahjoubi M, Cvitkovic E. Alexandre J, et al. Among authors: viens p. J Clin Oncol. 2000 Feb;18(3):562-73. doi: 10.1200/JCO.2000.18.3.562. J Clin Oncol. 2000. PMID: 10653871 Clinical Trial.
Results of a phase II trial with cystemustine at 90 mg/m(2) as a first- or second-line treatment in advanced malignant melanoma: a trial of the EORTC Clinical Studies Group.
Cure H, Souteyrand P, Ouabdesselam R, Roche H, Ravaud A, D'incan M, Viens P, Fargeot P, Lentz MA, Fumoleau P, Hanauske A, Chollet P. Cure H, et al. Among authors: viens p. Melanoma Res. 1999 Dec;9(6):607-10. doi: 10.1097/00008390-199912000-00011. Melanoma Res. 1999. PMID: 10661773 Clinical Trial.
436 results